GSK
GSK plc
$50.83
▲ 1.6%Updated Today 3:42 PM ET
GSK at a glance — five pillars scored 0–100 from real filed financials.
Overall: Favorable · 66/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 39.0% over the last 12 months
Market Cap
$102.51B
P/E
13.77x
Forward P/E (est.)
9.84x
ROE
35.8%
Revenue Growth
4.0%
EPS Growth
86.7%
Profit Margin
17.8%
FCF Yield
3.8%
Debt / Equity
1.08x
ROIC
20.0%
Interest Coverage
8.7x
Current Ratio
0.82x
Dividend Yield
3.5%
Implied Growth (rev. DCF)
1.0%
Rating Score
66/100
GSK plc (GSK) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $102.51B.
In its latest reported year it generated about $41.49B in revenue and $7.26B in net profit.
Our model rates GSK Favorable (66/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
71.8% average over the last 3 years
±2.5 pts around 68.1% across 10 years
grew in 8 of the last 9 year-over-year periods
positive in 10 of 10 years
20.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what GSK's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. GSK trades near $50.83, around its 50-day average ($51.55) and 200-day average ($50.67). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 50 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. GSK's is $1.25 (~2.5% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month GSK found buyers near $50.35 (support) and sellers near $53.84 (resistance); its 52-week range is $35.45–$61.70. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.6× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
7.2%
Revenue moved from $35.42B in 2016 to $41.49B in 2025, a 1.8% compound annual growth rate. The most recent year was roughly flat (4.0%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
72.4%
Operating Margin
24.3%
Net Margin
17.5%
ROE
35.8%
GSK plc keeps about 17.8% of each sales dollar as net profit, with a 72.4% gross margin and 24.3% operating margin. Return on equity is 35.8% and return on invested capital about 20.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$18.68B
Net Debt
$14.36B
Net Debt / EBITDA
1.43x
Debt / Equity
1.08x
Leverage: debt-to-equity is 1.1x, and operating profit covers interest about 8.7x, with a current ratio of 0.8x. That is a moderate, manageable debt load for most businesses. It carries roughly $18.68B of total debt against $4.31B of cash.
Operating CF
$9.83B
Free Cash Flow
$8.12B
FCF Margin
19.6%
In the latest year GSK plc produced about $9.83B of operating cash flow and $8.12B of free cash flow after capital spending. That is a free-cash-flow yield of about 3.8% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The dividend is being paid, but coverage or consistency is thinner than an income investor should rely on without a closer look.
Dividend yield
3.5%
Per share (latest FY)
$0.84
Total paid (latest FY)
$3.26B
History on record
10 years
dividend uses 40% of free cash flow
45% of net income paid out
total dividends increased 2 years in a row
payout was cut at least once in the last 10 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
13.77x
P/S
2.46x
P/B
4.51x
EV / EBITDA
8.98x
GSK trades at 13.8x trailing earnings (about 9.8x on estimated forward earnings), 2.5x sales, and 4.5x book value. Reverse-engineering today's price implies the market expects roughly 1.0% long-term free-cash-flow growth. That is an undemanding multiple — potentially cheap if the business is stable.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$32.25
Current price
$50.83
Starting FCF (latest 10-K)
$8.12B
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where GSK sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How GSK stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), GSK ranks #16 of 324 by our overall rating. It trades at a discount versus the sector on earnings (13.8x P/E vs. 25.4x median) with a higher return on equity (35.8% vs. 14.1%) and slower revenue growth (4.0% vs. 7.6%).
P/E vs sector
13.8x
median 25.4x
ROE vs sector
35.8%
median 14.1%
Growth vs sector
4.0%
median 7.6%
Sector rank
#16
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $50.83 today · expected CAGR -8% – 3%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $43.15B | $44.87B | $46.67B | $48.53B | $50.48B |
| Net income | $7.33B | $7.63B | $7.93B | $8.25B | $8.58B |
| EPS | $3.64 | $3.78 | $3.93 | $4.09 | $4.26 |
| Share price (low) | $29.10 | $30.26 | $31.47 | $32.73 | $34.04 |
| Share price (high) | $50.92 | $52.96 | $55.08 | $57.28 | $59.57 |
| CAGR (low–high) | -43% / 0% | -23% / 2% | -15% / 3% | -10% / 3% | -8% / 3% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for GSK:
- High net margins (17.8%) point to pricing power or efficiency.
- Strong return on equity (35.8%) shows capital is put to work well.
- Pays a 3.5% dividend on top of any price gains.
- Our model's overall read is Favorable (66/100).
The case against GSK:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Balance-sheet risk — debt/equity of 1.1x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: GSK plc is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 13.8x earnings, which our model scores Favorable (66/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 30 Wall Street analysts covering GSK recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+3 pts of buy ratings).
Latest SEC Filings
GSK's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
GSK — frequently asked questions
Is GSK a good stock to buy?
We don't give buy or sell advice. Our model rates GSK plc Favorable (66/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is GSK's rating on The Stocks School?
GSK plc currently scores 66/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does GSK's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from GSK plc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for GSK calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this GSK analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell GSK. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.